View in EDS HTML Full Text PDF Full Text

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.

Saved in:
Bibliographic Details
Title: Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
Authors: Weiden PJ; Alkermes, Inc., Waltham, MA, USA. pjweiden@gmail.com.; Karuna Therapeutics, 33 Arch Street, Suite 3110, Boston, MA, 02110, USA. pjweiden@gmail.com., Du Y; Alkermes, Inc., Waltham, MA, USA., von Moltke L; Alkermes, Inc., Waltham, MA, USA., Wehr A; Alkermes, Inc., Waltham, MA, USA., Hard M; Alkermes, Inc., Waltham, MA, USA.; Moderna, Inc., Cambridge, MA, USA., Marandi M; Radiant Clinical Research, Cerritos, CA, USA., Walling DP; CNS Network, LLC, Garden Grove, CA, USA.
Source: CNS drugs [CNS Drugs] 2020 Sep; Vol. 34 (9), pp. 961-972.
Publication Type: Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32621071
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Weiden+PJ%22">Weiden PJ</searchLink>; Alkermes, Inc., Waltham, MA, USA. pjweiden@gmail.com.; Karuna Therapeutics, 33 Arch Street, Suite 3110, Boston, MA, 02110, USA. pjweiden@gmail.com.<br /><searchLink fieldCode="AU" term="%22Du+Y%22">Du Y</searchLink>; Alkermes, Inc., Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22von+Moltke+L%22">von Moltke L</searchLink>; Alkermes, Inc., Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wehr+A%22">Wehr A</searchLink>; Alkermes, Inc., Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Hard+M%22">Hard M</searchLink>; Alkermes, Inc., Waltham, MA, USA.; Moderna, Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Marandi+M%22">Marandi M</searchLink>; Radiant Clinical Research, Cerritos, CA, USA.<br /><searchLink fieldCode="AU" term="%22Walling+DP%22">Walling DP</searchLink>; CNS Network, LLC, Garden Grove, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229431220%22">CNS drugs</searchLink> [CNS Drugs] 2020 Sep; Vol. 34 (9), pp. 961-972.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9431220 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1934 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211727047%22">11727047 </searchLink><i>NLM ISO Abbreviation: </i>CNS Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32621071
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40263-020-00745-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 961
    Titles:
      – TitleFull: Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Weiden PJ
      – PersonEntity:
          Name:
            NameFull: Du Y
      – PersonEntity:
          Name:
            NameFull: von Moltke L
      – PersonEntity:
          Name:
            NameFull: Wehr A
      – PersonEntity:
          Name:
            NameFull: Hard M
      – PersonEntity:
          Name:
            NameFull: Marandi M
      – PersonEntity:
          Name:
            NameFull: Walling DP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: 2020 Sep
              Type: published
              Y: 2020
          Identifiers:
            – Type: issn-electronic
              Value: 1179-1934
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: CNS drugs
              Type: main
ResultId 1